Skip to main content

Table 3 Associations between birthweight, childhood body size, puberty and breast cancer by menopausal and HER2 status

From: Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes

Characteristic

N

Pre-menopausal breast cancer

Postmenopausal breast cancera

HER2+ 

HER2−

HER2+ 

HER2−

Cases

HR (95% CI)

Cases

HR (95% CI)

Cases

HR (95% CI)

Cases

HR (95% CI)

Birthweight, per 500 g

117,493

76

0.94 (0.75–1.17)

392

1.00 (0.91–1.10)

346

0.95 (0.86–1.05)

2467

1.04 (1.00–1.08)

BMI, per z-score

Age 7 years

139,117

79

0.91 (0.73–1.13)

431

0.88 (0.80–0.97)

416

0.93 (0.84–1.03)

3089

0.88 (0.85–0.92)

Age 13 years

123,166

68

0.87 (0.68–1.10)

386

0.87 (0.79–0.96)

432

0.92 (0.83–1.02)

3176

0.88 (0.84–0.91)

Height, per z-score

Age 7 years

139,117

79

1.04 (0.83–1.29)

431

1.16 (1.05–1.28)

416

1.11 (1.01–1.23)

3089

1.08 (1.04–1.12)

Age 13 years

123,166

68

0.95 (0.74–1.20)

386

1.21 (1.10–1.34)

432

1.15 (1.05–1.27)

3176

1.13 (1.09–1.17)

Puberty markers, per year

Age at OGS

63,565

35

1.17 (0.91–1.50)

219

0.96 (0.87–1.06)

255

0.95 (0.86–1.05)

2012

0.99 (0.96–1.02)

Age at PHV

63,565

35

1.23 (0.93–1.63)

219

0.98 (0.88–1.10)

255

0.92 (0.83–1.02)

2012

1.01 (0.97–1.05)

  1. Associations were estimated in girls from the Copenhagen School Health Records Register followed from January 2007
  2. BMI body mass index, CI confidence interval, HR hazard ratio, HER2 human epidermal growth factor receptor 2, OGS onset of the growth spurt, PHV peak height velocity
  3. aAdjusted for use of hormone replacement therapy